167 related articles for article (PubMed ID: 22987022)
1. Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.
Cantilena L; Kahn R; Duncan CC; Li SH; Anderson A; Elkashef A
J Addict Med; 2012 Dec; 6(4):265-73. PubMed ID: 22987022
[TBL] [Abstract][Full Text] [Related]
2. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance.
Stoops WW; Blackburn JW; Hudson DA; Hays LR; Rush CR
Drug Alcohol Depend; 2008 Jan; 92(1-3):282-5. PubMed ID: 17719727
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.
Chamberlain SR; Del Campo N; Dowson J; Müller U; Clark L; Robbins TW; Sahakian BJ
Biol Psychiatry; 2007 Nov; 62(9):977-84. PubMed ID: 17644072
[TBL] [Abstract][Full Text] [Related]
10. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.
Wilens TE; Adler LA; Tanaka Y; Xiao F; D'Souza DN; Gutkin SW; Upadhyaya HP
Curr Med Res Opin; 2011 Dec; 27(12):2309-20. PubMed ID: 22029549
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wietecha LA; Williams DW; Herbert M; Melmed RD; Greenbaum M; Schuh K
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):719-30. PubMed ID: 20035590
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.
DeVito EE; Herman AI; Konkus NS; Zhang H; Sofuoglu M
Pharmacol Biochem Behav; 2017 Aug; 159():55-61. PubMed ID: 28716656
[TBL] [Abstract][Full Text] [Related]
13. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
Wilens TE; Gault LM; Childress A; Kratochvil CJ; Bensman L; Hall CM; Olson E; Robieson WZ; Garimella TS; Abi-Saab WM; Apostol G; Saltarelli MD
J Am Acad Child Adolesc Psychiatry; 2011 Jan; 50(1):73-84.e1. PubMed ID: 21156272
[TBL] [Abstract][Full Text] [Related]
15. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
Sert A; Gokcen C; Aypar E; Odabas D
Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
Thurstone C; Riggs PD; Salomonsen-Sautel S; Mikulich-Gilbertson SK
J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):573-82. PubMed ID: 20494267
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine-induced mydriasis in a child patient.
Bahali K; Ipek H; Yalcin O; Orum O
Eur Child Adolesc Psychiatry; 2014 Dec; 23(12):1231-2. PubMed ID: 24213458
[No Abstract] [Full Text] [Related]
19. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals.
Passamonti L; Luijten M; Ziauddeen H; Coyle-Gilchrist ITS; Rittman T; Brain SAE; Regenthal R; Franken IHA; Sahakian BJ; Bullmore ET; Robbins TW; Ersche KD
Psychopharmacology (Berl); 2017 Aug; 234(15):2289-2297. PubMed ID: 28551713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
